AR074418A1 - Compuestos de benzonaftiridina, procedimiento de preparacion y su uso en el tratamiento de tumores - Google Patents
Compuestos de benzonaftiridina, procedimiento de preparacion y su uso en el tratamiento de tumoresInfo
- Publication number
- AR074418A1 AR074418A1 ARP090104585A ARP090104585A AR074418A1 AR 074418 A1 AR074418 A1 AR 074418A1 AR P090104585 A ARP090104585 A AR P090104585A AR P090104585 A ARP090104585 A AR P090104585A AR 074418 A1 AR074418 A1 AR 074418A1
- Authority
- AR
- Argentina
- Prior art keywords
- nnr2
- mono
- nhet
- hal
- nhet2
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 3
- 125000000520 N-substituted aminocarbonyl group Chemical group [*]NC(=O)* 0.000 abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 abstract 1
- 240000000543 Pentas lanceolata Species 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 239000004305 biphenyl Substances 0.000 abstract 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000169 tricyclic heterocycle group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Los compuestos de la fórmula 1 en donde D es Ar o Het1, Het1 es un heterociclo saturado, insaturado o aromático mono- o bicíclico con 1 a 4 átomos de N, O y/o S, que no está sustituido o que puede estar mono-, di- o trisustituido con Hal, A, OA, Ar, OH y/u =O, R1 puede ser en cada caso, de modo independiente entre sí, H, Hal, OA, OH, A, fenilo o CN mono- o polisustituido, Het2 es un heterociclo saturado monocíclico con 1-3 átomos de N y/u O, que no está sustituido o que puede estar mono- o disustituido con =O, R4 puede ser en cada caso, de modo independiente entre sí, H, Hal, OA, OH, A, mono- o polisustituido, X, Y en cada caso, de modo independiente entre sí, están ausentes son -CH2-, -(CH2)2-, -CO- o -CHOH-, en donde sólo puede estar ausente uno de los radicales X o Y, R2, R3 son en cada caso, de modo independiente entre sí, R; R2 y R3 también son juntos una cadena de alquilos C2-6, en donde también un grupo CH2 puede estar reemplazado por O, NH o NA'; A' es alquilo C1-6, o CH2CH2OH, COO(CH2)nAr, (CH2)nAr, (CH2)nHet2, (CH2)nNA2 o Cyc, R5 puede ser H, Hal, NH2, OH, OA o A, R puede ser H, A, Cyc, (CH2)nAr o (CH2)nHet mono- o polisustituido, Z es O, NH, -CH(CONHA)NH-, CH2NHCONH, -CH=CH- o está ausente, Cyc es alquilo cíclico C3-7, A es alquilo lineal o ramificado C1-10, en donde 1-7 átomos de H pueden estar reemplazados por OR, CN, NR2, F y/o Cl y/o en donde uno o dos grupos CH2 no adyacentes pueden estar reemplazados por O, NH, S, SO, SO2 y/o por grupos CH=CH, o es alquilo cíclico C3-7, Ar es fenilo, indanilo, naftilo o bifenilo no sustituido o mono-, di-, tri-, tetra- o pentasustituido con Hal, A, (CR2)nOR, O(CR2)nAr2, (CR2)nNR2, SR, NO2, CN, COOR, CONR2, NRCOA, NRSO2A, SO2NR2, S(O)mA, CO-Het, (CR2)nHet, O(CR2)nNR2, O(CR2)nHet, NHCOOA, NHCONR2, NHCOO(CR2)nNR2, NHCOO(CR2)nHet, CR=CRAr2, SO2Het, NHCONH(CR2)nNR2, NHCONH(CR2)nHet, OCONH(CR2)nNR2, CONH(CR2)nHet, CONR(CR2)nNR2, CONR(CR2)nHet y/o COA; Het es un heterociclo mono-, di- o tricíclico saturado, insaturado o aromático con 1 a 4 átomos de N, O y/o S, que no está sustituido o que puede estar mono-, di- o trisustituido con Hal, A, Ar2, O(CR2)nAr2, (CR2)nOR, (CR2)nNR2, SR, NO2, CN, COOR, CONR2, NRCOA, NRSO2A, SO2NR2, S(O)qA, CO-Het2, (CR2)nHet2, O(CR2)nNR2, O(CR2)nHet2, NHCOOA, NHCONR2, NHCOO(CR2)nNR2, NHCOO(CR2)nHet, NHCONH(CR2)nNR2, NHCONH(CR2)nHet2, OCONH(CR2)nNR2, OCONH(CR2)nHet2, CO-Het2, CHO, COA, =S, =NH, =NA y/u =O; Hal es F, Cl, Br o I; n es 0, 1 o 2, m es 0, 1, 2, 3, 4 o 5, p es 1, 2, 3 o 4, así corno sus sales y estereoisómeros farmacéuticamente aceptables, incluyendo sus mezclas en todas las proporciones. Se pueden utilizar para el tratamiento de tumores.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102008059578A DE102008059578A1 (de) | 2008-11-28 | 2008-11-28 | Benzo-Naphtyridin Verbindungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074418A1 true AR074418A1 (es) | 2011-01-19 |
Family
ID=42107404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104585A AR074418A1 (es) | 2008-11-28 | 2009-11-27 | Compuestos de benzonaftiridina, procedimiento de preparacion y su uso en el tratamiento de tumores |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20110230471A1 (es) |
| EP (1) | EP2352733A1 (es) |
| JP (1) | JP2012509916A (es) |
| KR (1) | KR20110095392A (es) |
| CN (1) | CN102227426A (es) |
| AR (1) | AR074418A1 (es) |
| AU (1) | AU2009319421A1 (es) |
| BR (1) | BRPI0921860A2 (es) |
| CA (1) | CA2744833A1 (es) |
| DE (1) | DE102008059578A1 (es) |
| EA (1) | EA201100880A1 (es) |
| IL (1) | IL213052A0 (es) |
| MX (1) | MX2011005531A (es) |
| WO (1) | WO2010060532A1 (es) |
| ZA (1) | ZA201104749B (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
| WO2013054185A1 (en) * | 2011-10-13 | 2013-04-18 | Pfizer, Inc. | Pyrimidine and pyridine derivatives useful in therapy |
| WO2013070879A1 (en) | 2011-11-10 | 2013-05-16 | Bristol-Myers Squibb Company | Methods for treating spinal cord injury with lpa receptor antagonists |
| HRP20161774T1 (hr) | 2012-06-13 | 2017-02-24 | F. Hoffmann - La Roche Ag | Novi diazaspirocikloalkan i azaspirocikloalkan |
| BR112015004111A2 (pt) | 2012-09-25 | 2017-07-04 | Hoffmann La Roche | novos derivados bicíclicos |
| CN104144919B (zh) * | 2012-09-27 | 2018-07-03 | 山东营东颖昊生物科技有限公司 | 茶氨酸衍生物与羧酸香豆素衍生物的缩合产物及其中间体、其制备方法和用途 |
| ES2715682T3 (es) | 2012-12-19 | 2019-06-05 | Novartis Ag | Inhibidores de la autotaxina |
| US9409895B2 (en) | 2012-12-19 | 2016-08-09 | Novartis Ag | Autotaxin inhibitors |
| US20160002247A1 (en) * | 2013-03-01 | 2016-01-07 | The University Of Tokyo | 8-substituted imidazopyrimidinone derivative having autotaxin inhibitory activity |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| DK3269716T3 (da) | 2013-03-14 | 2020-10-19 | Galapagos Nv | Hidtil ukendte forbindelser og farmaceutiske sammensætninger deraf til behandling af inflammatoriske lidelser |
| JP2016530209A (ja) | 2013-09-17 | 2016-09-29 | ファーマケア，インク． | ビニルオートタキシン阻害剤化合物 |
| US9951026B2 (en) | 2013-09-17 | 2018-04-24 | Pharmakea, Inc. | Heterocyclic vinyl autotaxin inhibitor compounds |
| JP2016531874A (ja) * | 2013-09-26 | 2016-10-13 | ファーマケア，インク． | オートタキシン阻害剤化合物 |
| EA201690880A1 (ru) | 2013-11-22 | 2016-12-30 | Фармакеа, Инк. | Тетрациклические ингибиторы аутотаксина |
| EP3878848A1 (en) | 2013-11-22 | 2021-09-15 | Sabre Therapeutics LLC | Autotaxin inhibiting indole compounds |
| KR20160087900A (ko) | 2013-11-26 | 2016-07-22 | 에프. 호프만-라 로슈 아게 | 신규한 옥타하이드로-사이클로부타[1,2-c；3,4-c'']다이피롤-2-일 |
| SG10201808102WA (en) | 2013-12-20 | 2018-10-30 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| KR20160128428A (ko) | 2014-03-26 | 2016-11-07 | 에프. 호프만-라 로슈 아게 | 오토탁신(atx) 및 리소포스파티드산(lpa) 생성 억제제로서의 축합형 [1,4]다이아제핀 화합물 |
| SI3122750T1 (sl) | 2014-03-26 | 2019-12-31 | F. Hoffmann-La Roche Ag | Biciklične spojine kot zaviralci proizvodnje avtotaksina (ATX) in lizofosfatidne kisline (LPA) |
| US9051320B1 (en) | 2014-08-18 | 2015-06-09 | Pharmakea, Inc. | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor |
| GB201501870D0 (en) | 2015-02-04 | 2015-03-18 | Cancer Rec Tech Ltd | Autotaxin inhibitors |
| GB201502020D0 (en) | 2015-02-06 | 2015-03-25 | Cancer Rec Tech Ltd | Autotaxin inhibitory compounds |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| EP4026549A1 (en) | 2015-05-27 | 2022-07-13 | Sabre Therapeutics LLC | Autotaxin inhibitors and uses thereof |
| JP6886967B2 (ja) | 2015-09-04 | 2021-06-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | フェノキシメチル誘導体 |
| AU2016328365B2 (en) | 2015-09-24 | 2020-04-23 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual ATX/CA inhibitors |
| RU2018112230A (ru) | 2015-09-24 | 2019-10-30 | Ф. Хоффманн-Ля Рош Аг | Бициклические соединения в качестве ингибиторов atx |
| JP6877413B2 (ja) | 2015-09-24 | 2021-05-26 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 二重ａｔｘ／ｃａ阻害剤としての新規な二環式化合物 |
| CN107635995B (zh) | 2015-09-24 | 2022-08-19 | 豪夫迈·罗氏有限公司 | 作为atx抑制剂的二环化合物 |
| WO2018167113A1 (en) | 2017-03-16 | 2018-09-20 | F. Hoffmann-La Roche Ag | New bicyclic compounds as atx inhibitors |
| EP3596059B1 (en) | 2017-03-16 | 2024-04-24 | F. Hoffmann-La Roche AG | Heterocyclic compounds useful as dual atx/ca inhibitors |
| AU2022395102B2 (en) * | 2021-11-25 | 2025-09-11 | Shanghai Jeyou Pharmaceutical Co., Ltd. | Tricyclic derivative and preparation method therefor and application thereof |
| CN119591596B (zh) * | 2024-12-04 | 2025-10-17 | 沈阳药科大学 | 4,5-二氢-3H-吡咯并[2,3-c]喹啉-4-酮衍生物及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3889302T2 (de) * | 1987-12-03 | 1994-10-20 | Mitsubishi Chem Ind | 9-(Acylamino)tetrahydroacridinderivate und wahrnehmungssteigernde Mittel davon als aktiver Wirkstoff. |
| US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| CA2295309A1 (en) * | 1997-06-30 | 1999-01-07 | Nippon Kayaku Kabushiki Kaisha | Novel naphthyridine derivatives or salts thereof |
| GB9904387D0 (en) | 1999-02-25 | 1999-04-21 | Pharmacia & Upjohn Spa | Antitumour synergistic composition |
| EP1187633A4 (en) | 1999-04-08 | 2005-05-11 | Arch Dev Corp | USE OF ANTI-VEGF ANTIBODIES TO ENHANCE RADIATION IN ANTICANCER THERAPY |
-
2008
- 2008-11-28 DE DE102008059578A patent/DE102008059578A1/de not_active Withdrawn
-
2009
- 2009-11-05 BR BRPI0921860A patent/BRPI0921860A2/pt not_active Application Discontinuation
- 2009-11-05 JP JP2011537865A patent/JP2012509916A/ja active Pending
- 2009-11-05 KR KR1020117014790A patent/KR20110095392A/ko not_active Withdrawn
- 2009-11-05 EP EP09751814A patent/EP2352733A1/de not_active Withdrawn
- 2009-11-05 CN CN2009801476046A patent/CN102227426A/zh active Pending
- 2009-11-05 MX MX2011005531A patent/MX2011005531A/es unknown
- 2009-11-05 AU AU2009319421A patent/AU2009319421A1/en not_active Abandoned
- 2009-11-05 WO PCT/EP2009/007930 patent/WO2010060532A1/de not_active Ceased
- 2009-11-05 EA EA201100880A patent/EA201100880A1/ru unknown
- 2009-11-05 CA CA2744833A patent/CA2744833A1/en not_active Abandoned
- 2009-11-05 US US13/131,696 patent/US20110230471A1/en not_active Abandoned
- 2009-11-27 AR ARP090104585A patent/AR074418A1/es unknown
-
2011
- 2011-05-22 IL IL213052A patent/IL213052A0/en unknown
- 2011-06-27 ZA ZA2011/04749A patent/ZA201104749B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010060532A1 (de) | 2010-06-03 |
| BRPI0921860A2 (pt) | 2015-12-29 |
| AU2009319421A1 (en) | 2011-07-14 |
| JP2012509916A (ja) | 2012-04-26 |
| ZA201104749B (en) | 2012-03-28 |
| CA2744833A1 (en) | 2010-06-03 |
| MX2011005531A (es) | 2011-06-21 |
| IL213052A0 (en) | 2011-07-31 |
| CN102227426A (zh) | 2011-10-26 |
| DE102008059578A1 (de) | 2010-06-10 |
| US20110230471A1 (en) | 2011-09-22 |
| EA201100880A1 (ru) | 2012-01-30 |
| KR20110095392A (ko) | 2011-08-24 |
| EP2352733A1 (de) | 2011-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074418A1 (es) | Compuestos de benzonaftiridina, procedimiento de preparacion y su uso en el tratamiento de tumores | |
| AR068658A1 (es) | Derivados de tiazol | |
| AR073055A1 (es) | Derivados biciclicos de triazol | |
| AR068659A1 (es) | Derivados de imidazol inhibidores de autotaxina | |
| AR067506A1 (es) | Derivados de quinazolinamida | |
| AR068657A1 (es) | Derivados de piperidina y piperazina | |
| AR072098A1 (es) | Derivados de pirrolidina como inhibidores de metap-2 | |
| AR072860A1 (es) | Derivados de 3-(3-pirimidin-2-il-bencil)-[1,2,4]triazolo[4,3-b]piridazina | |
| AR071208A1 (es) | Derivados de piridazinona | |
| AR080803A1 (es) | Derivados de 3,4-dihidro-1h-benzo[b][1,6]naftiridina, composiciones farmaceuticas que los contiene, procedimiento para prepararlos e intermediarios del mismo, y uso de los compuestos en el tratamiento de canceres y enfermedades autoinmunes e inflamatorias. | |
| AR056986A1 (es) | Aza heterociclos como inhibidores de quinasas. procedimiento de obtencion y composiciones farmaceuticas | |
| AR072192A1 (es) | Derivados de tiazolil-piperidina | |
| AR082722A1 (es) | Derivados de pirimidina | |
| AR070649A1 (es) | Derivados de 1,3- dihidro -isoindol | |
| AR074493A1 (es) | Derivados de quinazolinamida | |
| AR072148A1 (es) | Derivados de quinoxalindiona | |
| AR061735A1 (es) | Derivados de indazol, composiciones farmaceuticas y uso de los mismos | |
| AR076006A1 (es) | Compuestos heterociclicos inhibidores de autotaxina utiles para el tratamiento de tumores, proceso para prepararlos y medicamentos que los contienen. | |
| AR057214A1 (es) | Derivados de piridazinona como inhibidores, reguladores o moduladores de quinasas. | |
| PE20110150A1 (es) | Amidofenoxiindazoles como inhibidores de c-met | |
| AR066543A1 (es) | Derivados de piridazinona | |
| AR081828A1 (es) | Compuestos de biguanida y su uso para el tratamiento del cancer | |
| AR066770A1 (es) | Derivados de piridazinona | |
| AR066892A1 (es) | Derivados de benzoxazolona, proceso, medicamento, uso para tratar tumores y kit | |
| AR067081A1 (es) | Derivados de pirrolo[2,3-b]piridin-pirimidina,proceso de preparacion, medicamentos que los contienen y usos de los mismos para el tratamiento de tumores cancerigenos y metastasis tumorales. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |